GENSCRIPT-BIOTECH
GenScript Biotech (Netherlands) BV , a subsidiary of GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a world-leading biotechnology company, and IES Diagnostics, the Life Science division of IES Medical, a company based in Spain, announced they have signed an agreement for the exclusive distribution of the GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in Spain, Portugal, and Andorra.
The test measures the presence of neutralizing antibodies (NAbs) in patients recovering from COVID-19 or receiving a vaccine. It is the only U.S. FDA Emergency Use Authorized (EUA) serology test for neutralizing antibodies from recent and prior SARS-CoV-2 infections. The kit is also CE marked (Europe) and has received HSA provisional approval (Singapore), ANVISA in Brazil, ANMAT in Argentina and has recently received clearance from the Ministry of Health and Prevention (MOHAP) in the United Arab Emirates as a medical device.
"With this collaboration, IES Diagnostics and GenScript will join forces to serve the local community with our expertise and resources. Since the outbreak of the worldwide pandemic in 2020, our company has been committed to supporting the global community in fighting COVID-19 with a comprehensive portfolio to support therapeutics and vaccine research and development, and diagnostic tool development including the novel cPass kit," said Aaron Qian, the President of European Division of GenScript.
Hubert Thomassen, CEO of IES Medical, said, "We are honored to be working with GenScript, proud to provide the unique and highly innovative cPass kit to our society that will contribute decisively to the knowledge of the immune status and level of protection of both those who have suffered a SARS-CoV-2 infection and those citizens who have been or will be vaccinated. The cPass kit is an essential tool in the development of any therapy aimed at combating this pandemic and in the development of an international immunity passport that allows our society to resume a normal social and economic life."
About GenScript Biotech Corporation
GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on its leading gene synthesis technology, GenScript has developed four major platforms including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform, and the industrial synthesis product platform. The company’s operations span over 100 countries and regions worldwide with legal entities located in the US, Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands, and Ireland. GenScript provides premium, convenient, and reliable products, and services for over 100,000 customers.
For more information visit http://www.genscript.com .
About IES Diagnostics
IES Diagnostics is the LifeScience division of IES Medical. IES Medical has its headquarters in Bilbao and offices in Madrid and Barcelona. The company directly serves clients all over the Iberian peninsula. IES Medical has a long-standing reputation for providing innovative products that contribute to improving the health of society in the areas of Emergency Medicine, Woundcare, Respiratory, and Diagnostics. The overall objective of IES Medical is to provide innovation for better care,
For more information visit https://www.iesmedical.es/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413006175/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Royal Decree Establishes the International Financial Centre of Oman13.1.2026 10:15:00 CET | Press release
His Majesty Sultan Haitham bin Tarik, may God protect and preserve him, has issued a Royal Decree establishing the International Financial Centre of Oman (IFC Oman) and enacting its own dedicated law. The establishment of the International Financial Centre of Oman aligns with the Sultanate of Oman’s strategic directions aimed at diversifying the national economy, strengthening Oman’s position as a global hub for financial services, attracting capital, and supporting innovation. The creation of the Centre also reflects Oman’s commitment to building a trusted and effective ecosystem for delivering advanced financial services that meet the needs of investors and global institutions. Under the Law of the International Financial Centre of Oman, issued by Royal Decree No. (8/2026), the Centre shall have administrative, financial, and legislative independence. It will develop a regulatory, legal, and judicial framework aligned with international standards and based on English Common Law. The
Forrester: AI-Led Job Disruption Will Escalate, While Fears Of A Job Apocalypse Are Overstated13.1.2026 10:00:00 CET | Press release
Only 6% Of Jobs In The US Will Be Automated By 2030 Forrester (Nasdaq: FORR) forecasts that automation and AI will have a real but modest impact on jobs through 2030. While AI could account for 6% of total US job losses, equating to 10.4 million roles, widespread AI-driven job replacement remains unlikely, as labor productivity would need to accelerate significantly for AI to replace human talent at scale. Rather than eliminating roles, Forrester forecasts that AI will augment 20% of jobs over the next five years, making it essential for businesses to invest in employee training and upskilling. According to the new report, The Forrester AI Job Impact Forecast, US, 2025–2030, over-automating roles due to the hype surrounding AI can lead to costly pullbacks, damaged reputations, and weakened employee experiences. Forrester’s 2026 future-of-work predictions further reveal that over half of layoffs attributed to AI will be quietly reversed as companies realize the operational challenges of
AI EdgeLabs Adds Advanced Risk and Compliance Center with Linux Audit Capabilities to Its AI Runtime Platform13.1.2026 10:00:00 CET | Press release
AI EdgeLabs, the pioneer in autonomous AI runtime platform, today announced the launch of Compliance Center and Linux Audit. Purpose-built for organizations facing NIS2, CRA, and global critical-infrastructure mandates, the new capabilities replace manual reporting and scan-based compliance with continuous visibility, automated control coverage, and real-time posture insights. Key capabilities include: A single Risk Score representing their current posture Real-time compliance visibility for CRA and NIS2 Prioritized assets based on impact and criticality Extended support for firmware, custom OS, and RTOS Linux audit and configuration hardening insights Automated, framework-specific checklists Incident Reporting and Automated Response “As NIS2 and the Cyber Resilience Act come into force, companies need continuous proof of compliance, not manual mapping or siloed visibility,” said Inna Ushakova, CEO of AI EdgeLabs. “This release provides real-time compliance posture, instant detection o
KAYTUS Introduces One-Stop End-to-End Liquid-Cooled Datacenter Solution Targeting AI Market13.1.2026 09:02:00 CET | Press release
- Enhances competitiveness with 30% reduction in cooling energy consumption - Supports high-density, high-efficiency, and eco-friendly data center construction through 4D differentiation strategy KAYTUS, a leading provider of end-to-end AI and liquid cooling solutions, has introduced its One-Stop End-to-End Liquid-Cooled Data Center Solution in response to the surging demand for AI adoption and energy efficiency. The solution is designed with the concepts of modularization, prefabrication, and safety, supporting up to 15 kW per node and 130 kW per cabinet, with a PUE below 1.1. It provides an end-to-end liquid cooling solution covering design, development, deployment, and operation, addressing the complexity and high entry barriers of large-scale liquid-cooled deployment while supporting eco-friendly data center operations aligned with the government’s carbon neutrality initiatives. Rapid Growth of Domestic AI Market Highlights Urgent Need for Energy Efficiency The AI industry is rapid
The Blind Sailor Takes the Stage at WEF: "HIRO’s CHOICE" Project to Set Sail13.1.2026 05:00:00 CET | Press release
A Solo, Non-Stop Crossing of the Pacific Ocean “Blind Sailor Single-Handed Pacific Crossing Project 2027” is a world-first initiative in which Mitsuhiro Iwamoto, a completely blind Japanese yachtsman (blind sailor) based in San Diego, will attempt a solo, non-stop trans-Pacific crossing in the spring of 2027. Sailing a 28-foot yacht single-handedly, he aims to cross the Pacific Ocean from San Diego on the U.S. West Coast to Amakusa, Kumamoto Prefecture, Japan, without making port. Iwamoto will speak about this project at the World Economic Forum Annual Meeting 2026, to be held in January 2026. Project URL: https://hiros-choice.com/ This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108087321/en/ Hiro Iwamoto / Global Keynote Speaker, First Totally Blind Sailor to Cross the Pacific The message he most wishes to convey at the WEF is the power of choice. He lost his sight at the age of sixteen—a moment when he nearly gave up on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom